Coronary heart disease combined with abnormal lipid metabolism
Conditions
Interventions
Control:Jiawei Huoxue Wengtong Formula Granules Placebo
JWHXWT:Jiawei Huoxue Wengtong Formula Granules
Sponsors
China Academy of Chinese Medical Sciences Eye Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Meets the diagnostic criteria for both stable coronary heart disease and abnormal lipid metabolism; (2) Meet the diagnostic criteria of Yang deficiency and cold condensation syndrome; (3) Age 18-75 years old male and female; (4) Patients voluntarily participated in the trial and signed an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Those with combined hypertrophic cardiomyopathy rheumatic heart disease pulmonary heart disease severe valvular disease dilated cardiomyopathy myocarditis severe arrhythmia and moderate to severe heart failure; (2) Those who have undergone percutaneous coronary intervention or coronary artery bypass grafting or implantation of pacemaker within the past 3 months; (3) Those with a combination of other diseases that may cause chest pain; (4) Those with secondary dyslipidaemia (e.g. dyslipidaemia caused by medication taken within 4 weeks hypothyroidism etc.); (5) Difficult-to-control hypertension as evidenced by systolic blood pressure (SBP) = 180 mmHg or diastolic blood pressure (DBP) = 100 mmHg; (6) Hepatic and renal insufficiency. Hepatic insufficiency is defined as an alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) value higher than two times the upper limit of the reference value and renal insufficiency is defined as a serum creatinine value higher than 1.5 times the upper limit of the reference value; (7) Women who are pregnant or breastfeeding; (8) Those suffering from severe psychological disorders mental retardation or speech disorders; those suffering from severe haematopoietic disorders; and those suffering from malignant tumours; Those who are allergic to study drugs; those who have participated in other clinical studies in the last 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seattle Angina Questionnaire; | — |
Secondary
| Measure | Time frame |
|---|---|
| Low-Density Lipoprotein Cholesterol,LDL-C;EQ-5D;deep capillary plexus, DCP;Total Cholesterol, TC ;Thickness of retinal nerve fibre layer ,RNFL;foveal avascular zone,FAZ;CT-FFR;Fasting Plasma Glucose;Chinese Medicine Score;High density lipoprotein cholesterol,HDL-C;Lp(a);superficial capillary plexus, SCP;Triglyceride,TG; | — |
Countries
China
Contacts
Public ContactYao Kuiwu
China Academy of Chinese Medicine
Outcome results
None listed